エピソード

  • Three Major Acquisitions Announced in Ophthalmology

    Three Major Acquisitions Announced in Ophthalmology
    2026/08/12
    Tarsus Pharmaceuticals enters into a definitive agreement to acquire Alkeus Pharmaceuticals; Harrow acquires dry eye disease nasal spray Tyrvaya from Viatris; and Italy-based Alfasigma enters into a share purchase agreement with Sever Life Sciences to acquire 100% of Nordic Pharma and its subsidiaries. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    6 分
  • Biocon Launches Eylea Biosimilar Yesafili

    Biocon Launches Eylea Biosimilar Yesafili
    2026/08/05
    An interchangeable biosimilar to Eylea is launched in the US; patient enrollment is completed in two global phase 3 clinical trials evaluating Duravyu for diabetic macular edema; and Topcon receives CE mark for a fully automated ultra-widefield retinal slit scanner. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    4 分
  • FDA Approves Outlook's Lytenava for Wet AMD

    FDA Approves Outlook's Lytenava for Wet AMD
    2026/07/29
    The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    12 分
  • PRIMA Retinal Implant Launched in EU

    PRIMA Retinal Implant Launched in EU
    2026/07/22
    A retinal implant system allowing patients with GA to regain some functional central vision vison is approved in Europe; Bausch + Lomb launches a new preloaded IOL delivery system in the US; and we review recent advancements and milestones in the development of novel ophthalmic treatments. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    6 分
  • Tarsus Buys Investigational Ocular Antiseptic

    Tarsus Buys Investigational Ocular Antiseptic
    2026/07/15
    Tarsus acquires the maker of an investigational ocular antiseptic; Alcon and RxSight partner to jointly develop adjustable PCIOLs; and the FDA will hold a meeting to discuss Sydnexis’ investigational low-dose atropine therapy for myopia. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    6 分
  • Viridian Executive Discusses FDA Approval of New TED Therapy

    Viridian Executive Discusses FDA Approval of New TED Therapy
    2026/07/01
    An executive from Viridian discusses the FDA approval of Lumvoa for thyroid eye disease (TED); a biosimilar referencing Lucentis is relaunched in the US; and Lumibird introduces a wireless integrated laser-indirect-ophthalmoscope. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    14 分
  • Ocular Updates Plans for Axpaxli NDA for Wet AMD

    Ocular Updates Plans for Axpaxli NDA for Wet AMD
    2026/06/24
    Ocular Therapeutix provides a key update on its NDA plans for wet AMD drug candidate Axpaxli; Thea US launches a first-of-its-kind eye gel for glaucoma; and there were several recent milestones reached in the clinical development of novel drugs for a variety of ocular conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    7 分
  • Tecnis PureSee IOL Fully Launched in the US

    Tecnis PureSee IOL Fully Launched in the US
    2026/06/17
    Johnson & Johnson expands the availability of its latest Tecnis lens; Bayer completes its acquisition of Perfuse Therapeutics, expanding its presence in ophthalmology; and ophthalmic leaders discuss how to navigate the current regulatory environment of the FDA. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    7 分